Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Laurie H. Sehn, Randy D. Gascoyne
Blood (2014) Vol. 125, Iss. 1, pp. 22-32
Closed Access | Times Cited: 506

Showing 1-25 of 506 citing articles:

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 26, pp. 2531-2544
Open Access | Times Cited: 4808
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster, Michael Bishop, Constantine S. Tam, et al.
New England Journal of Medicine (2018) Vol. 380, Iss. 1, pp. 45-56
Open Access | Times Cited: 3328
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump, Sattva S. Neelapu, Umar Farooq, et al.
Blood (2017) Vol. 130, Iss. 16, pp. 1800-1808
Open Access | Times Cited: 1383
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil, Michael D. Jain, Lei Feng, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 27, pp. 3119-3128
Open Access | Times Cited: 632
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, et al.
Molecular Therapy (2017) Vol. 25, Iss. 1, pp. 285-295
Open Access | Times Cited: 567
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron M. Goodman, Sandip Pravin Patel, Razelle Kurzrock
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 4, pp. 203-220
Closed Access | Times Cited: 416
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 24, pp. 2220-2231
Open Access | Times Cited: 382
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo, Marek Trněný, David Belada, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 31, pp. 3529-3537
Closed Access | Times Cited: 364
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 6, pp. 790-800
Closed Access | Times Cited: 328
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.
The Lancet Haematology (2020) Vol. 7, Iss. 7, pp. e511-e522
Open Access | Times Cited: 279
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Davide Rossi, Fary Diop, Elisa Spaccarotella, et al.
Blood (2017) Vol. 129, Iss. 14, pp. 1947-1957
Open Access | Times Cited: 221
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Catherine Thiéblemont, Hervé Tilly, María Gomes da Silva, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 22, pp. 2473-2481
Closed Access | Times Cited: 174
Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
Caron A. Jacobson, Frederick L. Locke, Long Ma, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 9, pp. 581.e1-581.e8
Open Access | Times Cited: 129
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
N. George Mikhaeel, Martijn W. Heymans, Jakoba J. Eertink, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 21, pp. 2352-2360
Open Access | Times Cited: 88
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, et al.
Blood Advances (2023) Vol. 7, Iss. 17, pp. 4926-4935
Open Access | Times Cited: 43
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
Christian Gisselbrecht, Éric Van Den Neste
British Journal of Haematology (2018) Vol. 182, Iss. 5, pp. 633-643
Open Access | Times Cited: 156
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
T. Lamy, Gandhi Damaj, Pierre Soubeyran, et al.
Blood (2017) Vol. 131, Iss. 2, pp. 174-181
Open Access | Times Cited: 153
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
Imane Azzaoui, Fabrice Uhel, Delphine Rossille, et al.
Blood (2016) Vol. 128, Iss. 8, pp. 1081-1092
Open Access | Times Cited: 151
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
John Kuruvilla, Michael R. Savona, Rachid Baz, et al.
Blood (2017) Vol. 129, Iss. 24, pp. 3175-3183
Open Access | Times Cited: 139
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
Austin J. Sim, Michael D. Jain, Nicholas B. Figura, et al.
International Journal of Radiation Oncology*Biology*Physics (2019) Vol. 105, Iss. 5, pp. 1012-1021
Open Access | Times Cited: 139
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Ziju Y. Xu-Monette, Min Xiao, Qingyan Au, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 4, pp. 644-657
Open Access | Times Cited: 135
Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy
Kui Li, Hongqi Tian
Journal of drug targeting (2018) Vol. 27, Iss. 3, pp. 244-256
Closed Access | Times Cited: 122
A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers
MoonSun Jung, Amanda J. Russell, Bing Liu, et al.
Cancer Research (2016) Vol. 77, Iss. 4, pp. 971-981
Open Access | Times Cited: 121
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
Laurie H. Sehn, Maurizio Martelli, Marek Trněný, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 120
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 8, pp. 1076-1088
Closed Access | Times Cited: 118
Page 1 - Next Page

Scroll to top